Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 36

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
2024, resulting from our loss of $11.0 million, partially offset
by changes in our net operating assets and liabilities of $1.7 million and non-cash stock-based compensation of $1.8 million. The change
in our net operating assets and liabilities was mainly due to an increase in accounts payable and accrued liabilities of $1.4 million
and a decrease in prepaid expenses of $0.4 million.

Financing Activities

During the three months ended
March 31, 2025, the Company sold 649,860 shares of common stock in exchange for net proceeds of $5.3 million.

During the three months ended
March 31, 2024, the Company repaid $2.5 million of its debt.

Critical Accounting Policies and Estimates

Our discussion and analysis
of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have
been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. Actual results
may differ from these estimates. Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2024, and there have been no material changes during the three months ended March 31, 2025.

26

Item 3. Quantitative and Qualitative Disclosures
About Market Risk

Pursuant to Item 305(e) of
Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller
reporting company,” as defined by Rule 229.10(f)(1). 

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our
management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”)) at the end of the period covered by this quarterly report.

Based
on this evaluation, we concluded that, as of such date, our disclosure controls and procedures were effective to provide reasonable assurance
that the information required to be disclosed by us in the reports we file or submit